Absinthe, epileptic seizures and Valentin Magnan by Eadie, M. J.
history
73
J R Coll Physicians Edinb 2009; 39:73–8
© 2009 Royal College of Physicians of Edinburgh
introduction
Absinthe is a bitter-tasting, greenish alcoholic liquor. Some 
of its constituents are, at least nominally, derived from the 
wormwood plant, Artemisia absinthium (see Figure 1). 
Absinthe was very frequently consumed in Western 
Europe, especially in France, in the latter part of the 
nineteenth century and came to achieve a notorious 
reputation, although alcoholic solutions containing 
wormwood-derived materials had been in medicinal use 
since ancient times without causing apparent problems. 
Wormwood itself was mentioned as a therapeutic agent 
in the Ebers papyrus1a of the sixteenth century BC and in 
Pliny’s first-century Natural History.1b Wine of absinth 
(oinos apsinthites) was described in the first-century Greek 
Herbal of Dioscorides. In this work, in the words of 
Goodyer’s English translation of 1655,2 the wine was 
reportedly ‘made divers ways’ and was:
 
good for ye stomach, ureticall, good for ye slow of 
digestion, for ye sick-liver, & ye Nepriticall, and ye 
Ictericall, for such as want appetite, & ye aggrieved at 
ye stomach & for ye long continued distension of ye 
Hypochondria and for inflations, & ye round-wormed, 
for ye restrained menstrual.
As the word ‘absinth’ has sometimes been applied to the 
wormwood plant and the very similar ‘absinthe’ to the 
beverage, to avoid confusion in the remainder of this paper 
‘absinthe’ has been used to refer only to the drink 
and ‘wormwood’ to the plant, even when it was termed 
‘absinth’ or its full botanical name was used in the original. 
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plant. It was widely consumed in France in the late nineteenth century. Its 
production was banned in 1915, partly because it was thought to cause 
neurological disturbances, including mental changes and epileptic seizures. 
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the standards of his time, and that he had shown that an alcohol-soluble 
component of wormwood did produce lapses of consciousness, myoclonic jerks 
and tonic-clonic convulsions in animals. Whether that component, presumably 
thujone, was present at convulsant concentrations in some of the available 
absinthes of Magnan’s time cannot now be known.
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Figure 1 Illustration of wormwood from J Hill’s The family 
herbal (Bungay: Brightly & Co; 1812).
The absinthe available for human consumption in the 
past two centuries, with its high concentration of ethyl 
alcohol (45–75%), was developed from a formula that 
originated in Switzerland late in the eighteenth century.3,4 
Classically, the beverage was made by distilling an 
alcoholic extract of the dried above-ground parts of the 
wormwood plant. Further quantities of materials 
obtained from wormwood and various other herbs 
(most commonly anise and fennel) were then added to 
a particular fraction of the distillate. The green colour 
finally obtained was due to extracted chlorophyll. 
As the years passed, many modifications of the original 
method were devised in making marketed absinthes. 
Various additional herbal materials and dyes were 
sometimes added to provide a satisfactory colour, as well 
as certain chemicals to achieve other desirable visual and 
gustatory properties. The alcohol concentration in 
different absinthes varied, although it was always high 
enough to keep any added plant-derived oils in solution. 
At times, it seems that some commercial absinthes 
contained no material that originated from wormwood.5
By the mid-nineteenth century, absinthe had become a 
favourite aperitif of the French middle classes. Elaborate 
rituals were often involved in its preparation preliminary 
to intake. In brief, before drinking, the strongly alcoholic 
solution was slowly diluted with water containing 
dissolved sugar (to counter the bitterness of the 
absinthe) until the mixture became cloudy as the water-
insoluble herbal oils began to separate from solution. 
In the wake of the widespread infestation of the French 
vineyards with Phylloxera in 1864, there was a shortage of 
both wine and grape-derived alcohol. Absinthes then 
began to be made with cheaper, industrially produced 
ethyl alcohol. It was soon realised that such absinthe had 
become the cheapest source of drinkable alcohol generally 
available in France.  As a result, absinthe rapidly became 
the most popular form of alcoholic beverage drunk by the 
lower classes. It was also favoured by many French literary 
and artistic figures of the time, including Charles Baudelaire, 
Arthur Rimbaud, Emile Zola, Paul Gauguin and Henri de 
Toulouse-Lautrec, as well as by artists and writers from 
other countries, such as Edgar Allan Poe and Oscar Wilde. 
The mental disturbances of Vincent van Gogh have been 
attributed to his excessive intake of absinthe.5
By the end of the nineteenth century, absinthe had come 
to be regarded as a significant cause of mental illness and 
epileptic seizures. The existence of a syndrome, 
absinthism, involving substance dependence, hallu-
cinations, epileptic seizures and mental deterioration, 
was postulated. As a result, absinthe production was 
banned in France in 1915, and in various other Western 
European countries and in the United States between 
1905 and 1923.  The bans continued until recent times in 
the European Union and still exist in the US.
With the advent in recent years of sensitive and specific 
analytical methods, it became possible to investigate the 
composition of various absinthes and, in particular, to 
measure their contents of the chemical thujone, which 
was thought responsible for the alleged neurotoxicity of 
absinthe. The European Commission in 2003 specified 
what it considered safe contents of thujone for various 
strengths of alcoholic beverage.6 This knowledge 
permitted the lifting of the ban on absinthe production 
in Western European countries. 
An awareness of a reputedly safe thujone concentration 
in alcoholic beverages and the widened commercial 
availability of absinthe have resurrected the question of 
whether late nineteenth-century absinthes really 
possessed any toxicity beyond that attributable to their 
high alcohol concentrations.7,8 Padosch et al.4 and 
Lachenmeier et al.9 concluded that, purely on the basis 
of thujone content, it would seem unlikely that absinthe 
made according to the original Swiss recipe would 
have carried any major risk of neurotoxicity. As a con-
sequence of this information, present-day writers10,11 
have sometimes criticised the scientific work and 
interpretations of Valentin Magnan, whose laboratory 
and clinical studies in the 1870s and subsequent advocacy 
played a significant part in the banning of absinthe 
production in France nearly a century ago.
In fairness to Magnan, it is now impossible to know 
whether the actual compositions of the various absinthes 
that were available in France in his day were as modern-
day analytical chemistry suggests they should have been. 
Consequently, little additional light can be thrown on the 
justification of Magnan’s assessment of the neurotoxic 
menace of the absinthe of his time. Rather, the present 
paper explores the adequacy of Magnan’s investigational 
science in relation to the clinical issue of absinthe intake, 
its neurotoxicity and potential for producing epileptic 
seizures, and the contributions to the understanding of 
epileptic seizure mechanisms that emanated from 
Magnan’s investigations.
VAlentin MAgnAn’S cAreer
Valentin Jacques Joseph Magnan was born at Perpignan, 
in France, in 1835.11,12 He studied medicine at Montpellier 
and then worked at hospitals in Lyon before competing 
successfully in 1863 for an internship in Paris at the 
Bicêtre Hospital under Louis Marcé and at the Salpêtrière 
Hospital under Jean Pierre Falret. In 1867 he came to the 
attention of influential figures in Paris when he treated 
the Prince Imperial, the son of Louis Napoléon. Soon 
afterwards he was appointed to be in charge of the 
Admissions Office of the newly opened Sainte-Anne 
Asylum in Paris. All instances of mental illness that 
came to the attention of the Paris police were assessed 
initially at this institution, and their more definitive 
management was then organised. Magnan occupied this 
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influential appointment for the remainder of his 
professional career, retiring in 1912 and dying four years 
later. Although passed over in 1877 for the newly 
created Chair in Mental Disease in Paris, Magnan became 
perhaps the most considerable figure in French 
psychiatry of his time, and the leader of one of its 
main schools of thought.
Magnan’s professional achievements lay in three main 
areas. In the late 1860s and the following decade he 
worked on the clinical consequences of alcohol abuse, in 
particular of absinthe, and carried out animal experi-
mentation relevant to these matters. He continued to 
campaign against these abuses throughout the remainder 
of his life, but from the 1880s his interest expanded into 
the classification of mental illness.12 He believed that 
such illness should be categorised on the basis of its life-
long course and took up Bénédict Augustin Morel’s idea 
that was so influential in French psychiatry, viz that such 
illness was a moral degeneration. 
Magnan modified this interpretation, minimised its 
religious connotations and formed the view that there 
were two types of degeneracy, one being inherited and 
the other a chronic delusional insanity. Either type, but 
particularly the latter, could develop into dementia. 
Magnan’s ideas were not universally accepted in French 
psychiatric circles.13 The subsequent controversies in the 
national professional community resulted in a 
considerable delay to its acceptance of Emil Kraepelin’s 
subdivision of psychotic illness (apart from general 
paralysis of the insane) into manic-depressive disease 
and dementia praecox (later called schizophrenia). 
Towards the end of his professional activities and in his 
retirement, Magnan was before his time in advocating 
less enforced restriction of the mentally ill and the 
abandoning of straitjackets and other forms of restraint, 
and employing an open-ward policy with the early 
return of the sufferer into the community.
Magnan’s research relating to absinthe  
Magnan was not the first to note a possible association 
between excessive absinthe intake and the occurrence of 
epileptic seizures and mental disturbance. He himself gave 
credit for this to Auguste Motet at the Bicêtre, 
who in 1859 described instances of the association in a 
doctoral thesis submitted to the University of Paris.14 
Marcé, whom Magnan referred to as his ‘master’ at the 
Bicêtre, had also reported the matter in a paper published 
in 1864.15 Marcé claimed absinthe possessed a special 
action beyond that of its alcohol content because, 
unlike simple alcohol intoxication, it rapidly produced 
stupor, hebetude (dullness of mind), terrifying hallucinations 
and intellectual enfeeblement. He found that giving dogs 
2–3 g of wormwood essence produced trembling, mental 
dullness and stupor, and led to the appearances of 
profound terror. Doses of 3–8 g of wormwood essence 
caused epileptiform clonic convulsions, incontinence, 
stertorous respirations and death. 
An association between absinthe and convulsing had 
also been noted by the great French clinician Armand 
Trousseau.16 Trousseau described the case of Mr W., 
aged 38 in 1861, who when aged 25 ‘had well-marked 
epileptic fits, probably due to his excessive use of 
absinthe, for the fits disappeared after two years, and on 
his giving up drinking absinthe’. The time factors 
suggest that somewhere between 1850 and 1861 
Trousseau had recognised the association between 
absinthe and seizures, so that he probably had priority 
over the Bicêtre alienists in observing the association.
Magnan’s own work in the area began in 1864,17 while he 
was collaborating with Marcé. There were major 
publications from Magnan in 1869,18 a short monograph, 
Étude expérimentale et clinique sur l’alcoolisme19 (Figure 2), 
and a long paper20 in 1871 and a major monograph, 
De l’alcoolisme, de diverses formes de délire alcoolique et 
Absinthe, seizures and Valentin Magnan
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Figure 2 The title page of Valentin Magnan’s 1871 
monograph on alcoholism and absinthic epilepsy.
de leur traitment, in 1874,21 soon afterwards translated 
into English by Greenfield. Magnan also summarised his 
work in an English language paper which appeared in 
The Lancet in 1874.22 He reported some of his earlier 
investigations on more than one occasion in his later 
publications. It seems unlikely that all of his experimental 
observations were published under his name since, while 
he mentioned that he had worked on dogs, cats, rabbits, 
guinea pigs and various birds,18 nearly all his experimental 
details traced in print refer to studies carried out in 
dogs. However, Robert Amory, who had earlier 
collaborated with Magnan, published some of his own 
original data, some joint work with Magnan including 
studies in non-canine species and some of Magnan’s 
earlier work in North American medical literature.23
In 1864, Magnan described a 30-year-old male who on 
three separate occasions experienced vertiges (a term 
then used for brief non-convulsive epileptic seizures 
with impaired consciousness) and convulsive epileptic 
seizures at times when he was drinking absinthe, but 
never when he abstained.17 Magnan stated that he had 
encountered further instances of the association. From 
the experimental design of his laboratory studies, it 
seems that Magnan was aware of the need to 
distinguish between the roles of alcohol and of other 
absinthe constituents in provoking epileptic seizures and 
other manifestations of neurotoxicity.18 He took the 
precaution of always using wormwood oil from the same 
reputable manufacturer, and reported that alcoholic 
extracts of the following components of contemporary 
absinthes, given individually to dogs, even in large 
intragastric doses, did not evoke seizures: essences of 
anise (aniseed, Pimpinella anisum), badian (star-anise, 
Illicium anisatum) and angélique (Angelica archangelica); 
sweet flag (Calamus aromaticus), origen (oregano, 
Origanum vulgare), menthe (mint, Lamiaceae species) and 
mélisse (Melissa officinalis).19 Nor did alcohol itself. 
In contrast, 5 g of wormwood essence caused tonic-
clonic seizures and ‘hallucinations’ (i.e. behaviour as if the 
animal was hallucinating), whereas lower doses caused 
vertiges and brief secousses (i.e. myoclonic jerks or jolts) 
involving the head and anterior parts of the body. On the 
other hand, chronic daily alcohol intake in increasing 
quantities in a dog produced widespread tremblings, 
paraplegia (i.e. hind limb weakness – alcoholic peripheral 
neuropathy was not then widely known) and coma, all 
increasing after each intake of alcohol. The combination 
of alcohol and essence of wormwood in another dog 
resulted in tremblings, alcoholic paraplegia and 
epileptiform seizures. 
By present-day standards, the numbers of dogs Magnan 
studied would appear inadequate to permit well-based 
conclusions, although it is not clear whether Magnan had 
additional supporting data and had simply published 
accounts of representative experiments. If the latter was 
the case, Magnan had provided reasonable evidence that 
the components of wormwood essence that should have 
been present in absinthe could have conferred convulsant 
and other neurotoxic properties on the beverage. His 
studies also suggested that the pattern of absinthe-related 
epileptic events to be expected in humans would involve 
lapses in consciousness (absences, petit mal), myoclonic 
jerks and generalised tonic-clonic epileptic seizures, i.e. 
phenomena resembling those of a primary generalised 
epilepsy of juvenile myoclonic type.
Was this the pattern of the reported seizures associated 
with human absinthe abuse? Magnan described only the 
presence of generalised tonic-clonic seizures in several of 
his human cases. However, in Case XI in Greenfield’s 
translation of Magnan,21 the continued intake of absinthe 
was associated with ‘sudden faintings’, increasing ‘absences’ 
or faints and epileptic seizures. In Case XII, a 42-year-old 
male who drank absinthe and brandy to excess over 
some years experienced attacks of ‘vertigo’ (probably a 
translation into English of vertiges, i.e. minor non-convulsive 
epileptic seizures), muscle twitchings and then fits. Unless 
these two of the five human cases reported in Magnan’s 
monograph were instances of causally unrelated primary 
generalised epilepsy, it seems that absinthe in humans 
provoked epileptic phenomena of a pattern similar to that 
which occured in animals given essence of wormwood. 
At the time of Magnan’s studies, Herpin24 had very recently 
published the first clear description of what was to 
become known as the juvenile myoclonic type of primary 
generalised epilepsy. Therefore Magnan may not have 
appreciated the importance of the lapses and jerkings that 
he saw in his patient.
Magnan carried out additional work on epileptic seizures 
provoked by wormwood extract that was not directly 
relevant to the absinthe-epilepsy question. For instance, 
in two pigeons he showed that seizures induced by 
wormwood essence continued after the cerebral 
hemispheres had been removed surgically.19 In a dog kept 
alive by artificial respiration after its neuraxis had been 
severed at the cervico-medullary junction, he reported 
that intravenous wormwood essence caused jerking in 
the upper part of the animal’s body, followed by clonic 
and then generalised convulsing as the wormwood dose 
was increased. In 1873 he used an ophthalmoscope to 
look for retinal vessel changes during wormwood-
induced seizures in a dog, and in another animal made a 
trepan hole in the skull to inspect the superficial cerebral 
arteries during wormwood-induced seizures.20
Presumably Magnan was seeking evidence of the cerebral 
circulatory alterations that were at the time believed 
to underlie epileptogenesis, although he seemed to leave 
it to his readers to deduce the rationales of his 
experiments, and to interpret them. Some of Magnan’s 
observations had pharmacokinetic implications, which he 
again did not make explicit. In 1871 he reported that if 
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essence of wormwood was given to a dog together with 
alcohol, the expected convulsion was deferred for several 
hours, even though the smell of absinthe appeared rapidly 
on the animal’s breath.19 Did the alcohol delay the 
absorption of the convulsant agent in absinthe or slow its 
entry into the brain? Magnan provided an answer when a 
second dog was given alcohol by mouth. In this animal, 
subsequent intravenous essence of woodworm produced 
convulsing at the expected time. Therefore alcohol 
probably delayed the absorption of the convulsant 
component present in wormwood essence.
the neurotoxic Agent in worMwood
Magnan’s seemingly well-designed investigations made it 
clear that if absinthe possessed convulsant and other 
forms of neurotoxic activity, that activity probably resided 
in its wormwood-derived components. With advances in 
analytical chemistry it has been shown that wormwood 
oil contains thujone, a known convulsant, and that the 
bitter taste of wormwood derives at least in part from 
the content of absinthin.9 Other terpene lactones are also 
present. Thujone exists in two stereoisomeric forms 
(Figure 3), both of which possess convulsant properties. 
Some 70–90% of the total thujone in wormwood oil is in 
the form of the b-enantiomer,5 but the main biological 
activity resides in the a-enantiomer.25 
a-Thujone is a GABAA receptor non-competitive 
antagonist.25 Because its molecular structure resembles 
that of part of the cannabinoid molecule, it was at one time 
suggested that a cannabinoid-type action might be 
responsible for the hallucinatory and other psychological 
effects claimed for absinthe.26 More recent evidence does 
not support this interpretation.27 Thujone induces 
cytochrome P450 activity,25 and is porphyrinogenic.28 Because 
of this latter effect it was suggested that thujone in absinthe 
may have caused Vincent van Gogh’s hallucinations since he 
also happened to suffer from unrecognised porphyria.28 
Other GABAA receptor antagonists such as picrotoxinin 
and pentylenetetrazole (Metrazole)29 cause epileptic 
seizures in experimental animals and in humans, and the 
induced seizure pattern resembles that of a primary 
generalised epilepsy, with its interruptions of 
consciousness, multiple myoclonic jerks and, at higher 
dosages, generalised tonic-clonic convulsing. For a time 
pentylenetetrazole seizures were considered a model 
for human absence epilepsy, although the seizures 
produced resembled myoclonic jerks more closely 
than absence ones. It is also known that the 
oxazolidinedione family of drugs, effective in humans 
against petit mal absence seizures, prevents thujone-
induced seizures in animals.30
Taken together, these facts make it probable that 
a-thujone in the wormwood-derived component of 
absinthe was responsible for the association between 
absinthe intake and epileptic seizures that was noticed 
by Magnan and his contemporaries. While safe 
concentrations for thujone in alcoholic beverages have 
now been determined, and recent studies have shown 
that present-day absinthes prepared according to the 
original Swiss recipe should not have had dangerous 
thujone concentrations, it remains possible that some of 
the absinthes drunk by Magnan’s patients may have had 
higher thujone concentrations. It is also possible that 
some of Magnan’s patients may have had a genetic 
predisposition to juvenile myoclonic epilepsy, even 
though they had no past history of clinical seizures. Such 
persons might be expected to be unusually vulnerable to 
the epileptogenic consequences of thujone-induced 
GABAA receptor blockade.
diScuSSion
Modern scientific evidence lends some support to the 
belief of Magnan and some of his Parisian contemporaries 
that the absinthe of their time possessed the capacity to 
cause convulsing and other neurotoxic manifestations. 
Whether its convulsant principle (a-thujone), as distinct 
from alcohol itself, explained the reported hallucinatory 
and other psychological effects of excess absinthe intake 
is less clear. However, there can be little doubt that 
Magnan22 was being far-sighted when, in The Lancet, he 
wrote that the ‘essence of absinthe is a valuable agent 
for the study of the mechanism of epilepsy.’
Magnan himself used absinthe for this purpose, as 
described above, and it was employed by other 
investigators in the late nineteenth century to provoke 
epileptic seizures in experimental animals and then to 
study the effects of various cerebral manipulations on 
the induced seizure phenomena.31–35 In the early decades 
of the twentieth century, Howard Florey36 used it in his 
investigations on the cerebral circulation carried out in 
Charles Sherrington’s laboratory in Oxford.
Absinthe, seizures and Valentin Magnan
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Figure 3 Structural formulae of thujone enantiomers.
a-thujone b-thujone
Wormwood, as suggested by its name, has been a 
remedy for intestinal worms since ancient times, 
although herbals such as those of Diascorides2 and 
Culpeper37 were not particularly enthusiastic concerning 
its efficacy. At least from the Middle Ages onwards, 
intestinal worms were commonly regarded as a cause of 
epileptic seizures, particularly in children (for example 
by Bernard of Gordon,38 early in the fourteenth century). 
Although some nineteenth-century authors were more 
sceptical,39,40 the great neurological figure Sir William 
Gowers held as late as 1881 that: 
Acute convulsions frequently result from the irritation 
of various forms of intestinal worms in children and 
sometimes in adults. Usually, however, they cease 
when the worms are expelled.41
Because of the generations-old popular perception 
that there was a relationship between intestinal worms 
and convulsions in children and the continuing medical 
endorsement of this idea, it seems possible that the use 
of wormwood (with its content of convulsant thujone) to 
treat intestinal worms when their presence was recognised 
may have sometimes contributed to the occurrence of 
the convulsions it was intended to prevent. 
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